To identify whether tested drugs inhibit the acute leukemia relevant enzymes involved in anthracycline reduction, a pilot study was conducted using recombinant CBR1, AKR1C3, AKR1A1, AKR1B1, and AKR1B10. This evidence concerns the gene AKR1B1 and acute leukemia.